España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Relief Therapeutics
RLFTF
OTCQB
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$4.65
0.15
3.33%
At close: -
$4.50
-0.15
-3.23%
After Hours: Dec 19, 4:00 PM EDT
Get Report
Comment
Relief Therapeutics (RLFTF) Forecast
News
Earnings
Relief Therapeutics (RLFTF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Relief Therapeutics (OTC:RLFTF) Stock
Relief Therapeutics Stock (OTC: RLFTF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 22, 2024
Eton Pharmaceuticals Acquires Exclusive U.S. ...
Benzinga Newsdesk
Monday, November 14, 2022
Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate
Vandana Singh
Thursday, July 28, 2022
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Vandana Singh
Friday, July 01, 2022
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Shanthi Rexaline
Tuesday, June 21, 2022
FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate
Vandana Singh
Acer Therapeutics Says FDA Has Issued Complete Response Letter Regarding NDA For ACER-001, citing 'the need to inspect a third-party contract packaging manufacturer'; Says 'pharmacokinetics of ACER-001'
Bill Haddad
Sunday, June 05, 2022
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Shanthi Rexaline
Tuesday, May 31, 2022
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Shanthi Rexaline
Thursday, January 13, 2022
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Shanthi Rexaline
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights
Vandana Singh
Wednesday, January 12, 2022
NRx Pharma Reports Filing Of Counterclaim Aga...
Benzinga Newsdesk
Tuesday, December 14, 2021
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
Jad Malaeb
-
Sponsored
Wednesday, November 24, 2021
FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate
Vandana Singh
Friday, November 05, 2021
NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful
Vandana Singh
Wednesday, October 27, 2021
Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
Vandana Singh
Wednesday, October 06, 2021
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Shanthi Rexaline
Acer Therapeutics Stock Jumps As UCD Candidate Is Under FDA Review
Vandana Singh
Acer Therapeutics and Relief Therapeutics Announced FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders With PDUFA Target Action Date of June 5, 2022
Charles Gross
Tuesday, August 03, 2021
Relief Therapeutics' Lead Candidate Gets US Orphan Drug Tag In Sarcoidosis
Vandana Singh
Friday, July 23, 2021
Why NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
Vandana Singh
Tuesday, June 01, 2021
NRx Files for Zyesami Emergency Use in Critical COVID-19 Patients With Respiratory Failure
Vandana Singh
Monday, March 22, 2021
Acer Therapeutics Enters Into ACER-001 Development Pact With Relief Therapeutics
Vandana Singh
Relief and Acer Therapeutics Signed Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of UCDs and MSUD; , Acer to Receive ~$10M Cash Payment
Charles Gross
Monday, March 15, 2021
What's Happening With ACER Stock, MGM Stock, XPEV Stock?
Henry Khederian
Tuesday, February 09, 2021
Relief Therapeutics' COVID-19 Treatment Candidate Cuts Hospital Stay Versus Placebo, Recovery From Respiratory Failure Yet To Be Determined
Vandana Singh
Monday, January 25, 2021
Relief Therapeutics, Acer Therapeutics Signed Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease; Acer to Receive $1M Payment to Obtain Exclusivity and $4M Loan From Relief
Charles Gross
Tuesday, October 27, 2020
Traders Have Rotated Into Big Multinational Companies On OTC Markets
Spencer Israel